RAPT Rockets 180% on Licensing Deal, $150M Private Placement (Update)

RAPT Therapeutics (NASDAQ:RAPT) shares rallied as much as 180% on Monday after the company announced a worldwide licensing deal with China's Shanghai Jemincare for an allergy drug candidate and a $150 million private placement of its stock.

RAPT (NASDAQ:RAPT) said